Michael Barbella, Managing Editor04.01.22
VistaCare Medical is preparing to fast track the development and commercialization of its medical device for complex wound treatment.
"Thanks to the support of our financial investors and the Bourgogne Franche-Comté region, VistaCare Medical will begin a new phase of its existence," said François Dufaÿ, founding president of VistaCare Medical. "Improve and propose the expected evolutions of our medical devices, render their use possible through more care facilities, develop internationally, produce the devices we market while supporting local employment…all in the service of patients with serious wounds, this is what this new round will permit.”
Leveraging 4 million euros in funding from Noshaq, Cap Innov'Est, its historical shareholder, BFC Croissance & Innovation, Crédit Agricole Bourgogne Franche-Comté Region, WiSEED and DGO6 (region of Wallonia), as well as a grant from the Bourgogne Franche-Comté Region, VistaCare will:
Founded in 2010 in the Jura region, VistaCare Medical develops, produces, and commercializes the VistaCare medical device for treating complex wounds. VistaCare offers unrivaled results compared to conventional methods for complex wounds associated with arterial pathologies, burns or other injuries. Its use halves necessary hospitalization times helps accelerate healing. It improves the quality of life of the patient and allows to treat incurable cases that could lead to amputation.
“The VistaCare approach is radically different from conventional wound treatment practices to date. VistaCare gives physicians and caregivers control over the progression of the wound towards healing, making it more likely that patients will have effective and reproducible treatment regardless of where they are treated, including at home. Today, this is what allows us to attract the best KOLs and the talents that join our young team. This funding step is a major milestone in accelerating the growth of a future French and already European healthtech champion," VistaCare Medical Ceo Thierry Sarda said.
Already used in more than 30 hospitals, VistaCare reduces treatment time by 10 days on average, without dressing, by controlling and modulating the sterile atmosphere around the wound (humidity, oxygen, temperature), according to the WEC proprietary concept for "Wound Environment Control."
"We are pleased to welcome NoShaq, BFC Croissance & Innovation, Crédit Agricole, and WiSEED to continue the development of this very ambitious company that we have been supporting since 2015. This new operation will allow VistaCare Medical to fully develop and provide a truly effective solution for the treatment of no-contact wounds," commented Jean-François Rax, investment director, Capital Grand Est.
"Noshaq is pleased to contribute to this project which offers disruptive technology for the non-contact treatment of complex wounds. We are pleased to help the company develop its R&D and industrialization activities in the Liège area. The subject of medtechs is strategic for Noshaq, and we continue our strategy of attracting foreign companies in this field," declared Eric Brandt, investment manager, Noshaq.
"LallianSe has been supporting VistaCare since 2017. This is a unique and emblematic project that we are very proud to see progressing with an important milestone. VistaCare Medical has everything it takes to become a major player and its partnership approach in France and Europe is very representative of the LallianSe action at the heart of health ecosystems," added Julie Rachline, president of LallianSe.
VistaCare optimizes the physiological physico-chemical parameters necessary to accelerate the healing process allowing the treatment time of complex wounds to be halved. CE-marked, it is already used in several teaching hospitals.
VistaCare Medical is developing and commercializing medical devices for its wound management platform. The startup firm began developing VistaCare One in 2015 with its first seed financing round leading to CE certification in 2018. VistaCare Medical's head office is in Besançon employing today 12 people. A new office in Liège will foster the company's digital R&D and commercialization expansion in Europe. VistaCare Medical has BPI Excellence label, Medical Startup Awards Medica 2015 and finalist Prix Gallien Med Startup 2019. More than 300 patients have been treated by VistaCare One in more than 30 hospitals in France.
"Thanks to the support of our financial investors and the Bourgogne Franche-Comté region, VistaCare Medical will begin a new phase of its existence," said François Dufaÿ, founding president of VistaCare Medical. "Improve and propose the expected evolutions of our medical devices, render their use possible through more care facilities, develop internationally, produce the devices we market while supporting local employment…all in the service of patients with serious wounds, this is what this new round will permit.”
Leveraging 4 million euros in funding from Noshaq, Cap Innov'Est, its historical shareholder, BFC Croissance & Innovation, Crédit Agricole Bourgogne Franche-Comté Region, WiSEED and DGO6 (region of Wallonia), as well as a grant from the Bourgogne Franche-Comté Region, VistaCare will:
- Increase production in the Besançon industrial area, which specializes in medical devices, and thus contribute to the creation of about 60 industrial jobs in the long term,
- Bolster VistaCare Medical's European presence by creating a subsidiary in Belgium (VistaCare Medical Benelux)
- Accelerate marketing to hospital facilities in France and Europe,
- Develop R&D and finalize the connected outpatient version of VistaCare intended for the home in telemedicine,
- Recruit new employees.
Founded in 2010 in the Jura region, VistaCare Medical develops, produces, and commercializes the VistaCare medical device for treating complex wounds. VistaCare offers unrivaled results compared to conventional methods for complex wounds associated with arterial pathologies, burns or other injuries. Its use halves necessary hospitalization times helps accelerate healing. It improves the quality of life of the patient and allows to treat incurable cases that could lead to amputation.
“The VistaCare approach is radically different from conventional wound treatment practices to date. VistaCare gives physicians and caregivers control over the progression of the wound towards healing, making it more likely that patients will have effective and reproducible treatment regardless of where they are treated, including at home. Today, this is what allows us to attract the best KOLs and the talents that join our young team. This funding step is a major milestone in accelerating the growth of a future French and already European healthtech champion," VistaCare Medical Ceo Thierry Sarda said.
Already used in more than 30 hospitals, VistaCare reduces treatment time by 10 days on average, without dressing, by controlling and modulating the sterile atmosphere around the wound (humidity, oxygen, temperature), according to the WEC proprietary concept for "Wound Environment Control."
"We are pleased to welcome NoShaq, BFC Croissance & Innovation, Crédit Agricole, and WiSEED to continue the development of this very ambitious company that we have been supporting since 2015. This new operation will allow VistaCare Medical to fully develop and provide a truly effective solution for the treatment of no-contact wounds," commented Jean-François Rax, investment director, Capital Grand Est.
"Noshaq is pleased to contribute to this project which offers disruptive technology for the non-contact treatment of complex wounds. We are pleased to help the company develop its R&D and industrialization activities in the Liège area. The subject of medtechs is strategic for Noshaq, and we continue our strategy of attracting foreign companies in this field," declared Eric Brandt, investment manager, Noshaq.
"LallianSe has been supporting VistaCare since 2017. This is a unique and emblematic project that we are very proud to see progressing with an important milestone. VistaCare Medical has everything it takes to become a major player and its partnership approach in France and Europe is very representative of the LallianSe action at the heart of health ecosystems," added Julie Rachline, president of LallianSe.
VistaCare optimizes the physiological physico-chemical parameters necessary to accelerate the healing process allowing the treatment time of complex wounds to be halved. CE-marked, it is already used in several teaching hospitals.
VistaCare Medical is developing and commercializing medical devices for its wound management platform. The startup firm began developing VistaCare One in 2015 with its first seed financing round leading to CE certification in 2018. VistaCare Medical's head office is in Besançon employing today 12 people. A new office in Liège will foster the company's digital R&D and commercialization expansion in Europe. VistaCare Medical has BPI Excellence label, Medical Startup Awards Medica 2015 and finalist Prix Gallien Med Startup 2019. More than 300 patients have been treated by VistaCare One in more than 30 hospitals in France.